A Phase I, Multicenter, Open-Label Dose Escalation and Expansion Study of PCA062, Administered Intravenously In Adult Patients With pCAD-Positive Tumors (CTMS# 14-2019)
To determine the MTD/RDE of PCA062 in patients with pCAD-positive tumors in the dose escalation part.
To characterize the safety and tolerability of PCA062
To characterize the pharmacokinetic profile of PCA062
To assess emergence of anti-PCA062 antibodies following one or more intravenous infusions of PCA062
To assess the preliminary anti-tumor activity of PCA062 in patients with pCAD-positive triple negative breast cancer (TBNC), head and neck squamous cell carcinoma (HNSCC) or esophageal cancer (squamous and adenocarcinoma)
To enroll or if you have questions about participation